US FDA approves syringe version of Argenx's immune disorder drug-April 2024-www.financetom.com

US FDA approves syringe version of Argenx's immune disorder drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves syringe version of Argenx's immune disorder drug

Apr 10, 2025 3:16 PM

April 10 (Reuters) - The U.S. Food and Drug

Administration has approved a pre-filled syringe version of

Netherlands-based Argenx SE's blockbuster immune

disorder drug, Vyvgart, giving patients the more convenient

option of at-home self administration, the company said on

Thursday.

Previous page： AmEx says it identified 30 consumer accounts potentially tied to Iran's government Next page： BofA to buy $9 bln residential mortgage loan from Canada's TD, source says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

AmEx says it identified 30 consumer accounts potentially tied to Iran's government

Feb 7, 2025

Feb 7 (Reuters) - U.S. credit card giant American Express ( AXP ) said on Friday it had identified approximately 30 consumer accounts last year that might have been tied to the government of Iran. ...

BofA to buy $9 bln residential mortgage loan from Canada's TD, source says

Feb 7, 2025

Feb 7 (Reuters) - Bank of America ( BAC ) has agreed to buy a $9 billion portfolio of residential mortgage loans from Canadian lender Toronto-Dominion Bank ( MLWIQXX ), a source familiar with the matter said on Friday. ...

AbbVie Says FDA Approves Emblaveo Antibiotic to Treat Abdominal Infections

Feb 7, 2025

02:03 PM EST, 02/07/2025 (MT Newswires) -- AbbVie ( ABBV ) said Friday it received approval from the US Food and Drug Administration for its antibiotic Emblaveo for the treatment of adults with complicated intra-abdominal infections. The approval covers Emblaveo's use with metronidazole in patients who have limited or no alternative options to treat their infections, including those caused by...

Market Chatter: Magnite to Provide Programmatic Ad Sales Support to X

Feb 7, 2025

02:19 PM EST, 02/07/2025 (MT Newswires) -- Magnite ( MGNI ) is collaborating with Elon Musk's X to boost the social media platform's programmatic advertising sales, Business Insider reported Friday, citing Magnite's ( MGNI ) spokesperson. The partnership gives advertisers an option to add or remove X's inventory from their media buys, the spokesperson reportedly said. Neither Magnite ( MGNI...